GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients

Table 1

Main demographic and clinical data of the cohort of patients and phenotypic characteristics of the purified VEC.

Variable	Cohort (𝑛=20)*
Patient age (years)	57.8±9.7
Men/women	5/15
Body mass index (kg/m^2)	26.05±4.11
Age at CVD onset (years)	36.15±9.79
Relevant medical history: yes/no
Family history of CVD	17/2
DM2	2/18
Cardiac disease	1/19
Hypercholesterolemia	4/16
Hypertension	9/11
Current smoker	5/15
CEAP classification: C2/C3	8/12
Varicose veins surgery: CHIVA 1/CHIVA 2	13/7
Hemodynamic parameters
PSV (cm/s)	29±13
EDV (cm/s)	8±6
RI	1.31±0.19
RT (s)	2.66±0.46
VEC phenotypic properties:
CD31^+/CD105^+	93–98%
CD146^+/CD144^+	90–98%
CD45^−/CD14^−	0–0.9%
Surface ICAM-1 (MFI)	64.12±61.93
Surface VCAM-1 (MFI)	ND

∗Values are expressed as mean ± SD unless otherwise indicated.
CVD: chronic venous disease; DM2: diabetes mellitus type 2; CEAP: clinical signs, etiology, anatomic distribution, and pathophysiology; CHIVA: cure hémodynamique de l'insuffisance veineuse en ambulatoire; PSV: peak systolic velocity; EDV: end diastolic velocity; RI: resistance index; RT: reflux time; MFI: mean fluorescence intensity; ND: not detectable.